{"id":10130,"date":"2019-05-09T17:21:44","date_gmt":"2019-05-09T15:21:44","guid":{"rendered":"https:\/\/udic.es\/?p=10130"},"modified":"2024-02-14T16:07:10","modified_gmt":"2024-02-14T15:07:10","slug":"another-terapeutic-target-in-alzheimer-disease","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/","title":{"rendered":"Another terapeutic target in Alzheimer disease"},"content":{"rendered":"<p>We started a phase II \/ III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage Alzheimer&#8217;s disease. It involves a change in the therapeutic target hitherto chosen: the amyloid protein<\/p>\n","protected":false},"excerpt":{"rendered":"<p>We started a phase II \/ III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage Alzheimer&#8217;s disease. It involves a change in the therapeutic target hitherto chosen: the amyloid protein<\/p>\n","protected":false},"author":4,"featured_media":9510,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132,129],"tags":[],"class_list":["post-10130","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzeimer-en","category-alzeimer-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Another terapeutic target in Alzheimer disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"We started a phase II \/ III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Another terapeutic target in Alzheimer disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"We started a phase II \/ III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-09T15:21:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-14T15:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1156\" \/>\n\t<meta property=\"og:image:height\" content=\"762\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"SUSANA ANDRADE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"SUSANA ANDRADE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/\"},\"author\":{\"name\":\"SUSANA ANDRADE\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\"},\"headline\":\"Another terapeutic target in Alzheimer disease\",\"datePublished\":\"2019-05-09T15:21:44+00:00\",\"dateModified\":\"2024-02-14T15:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/\"},\"wordCount\":43,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg\",\"articleSection\":[\"Alzeimer\",\"Alzeimer\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/\",\"url\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/\",\"name\":\"Another terapeutic target in Alzheimer disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg\",\"datePublished\":\"2019-05-09T15:21:44+00:00\",\"dateModified\":\"2024-02-14T15:07:10+00:00\",\"description\":\"We started a phase II \/ III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg\",\"width\":1156,\"height\":762,\"caption\":\"ProfesionalUdic4\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Another terapeutic target in Alzheimer disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\",\"name\":\"SUSANA ANDRADE\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"caption\":\"SUSANA ANDRADE\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Another terapeutic target in Alzheimer disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"We started a phase II \/ III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/","og_locale":"en_US","og_type":"article","og_title":"Another terapeutic target in Alzheimer disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"We started a phase II \/ III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage","og_url":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2019-05-09T15:21:44+00:00","article_modified_time":"2024-02-14T15:07:10+00:00","og_image":[{"width":1156,"height":762,"url":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg","type":"image\/jpeg"}],"author":"SUSANA ANDRADE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"SUSANA ANDRADE","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#article","isPartOf":{"@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/"},"author":{"name":"SUSANA ANDRADE","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03"},"headline":"Another terapeutic target in Alzheimer disease","datePublished":"2019-05-09T15:21:44+00:00","dateModified":"2024-02-14T15:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/"},"wordCount":43,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg","articleSection":["Alzeimer","Alzeimer"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/","url":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/","name":"Another terapeutic target in Alzheimer disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg","datePublished":"2019-05-09T15:21:44+00:00","dateModified":"2024-02-14T15:07:10+00:00","description":"We started a phase II \/ III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage","breadcrumb":{"@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2018\/11\/ProfesionalUdic4.jpg","width":1156,"height":762,"caption":"ProfesionalUdic4"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/another-terapeutic-target-in-alzheimer-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"Another terapeutic target in Alzheimer disease"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03","name":"SUSANA ANDRADE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","caption":"SUSANA ANDRADE"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=10130"}],"version-history":[{"count":1,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10130\/revisions"}],"predecessor-version":[{"id":10131,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10130\/revisions\/10131"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media\/9510"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=10130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/categories?post=10130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/tags?post=10130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}